Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Alimentary Pharmacology & Therapeutics, Wiley, Vol. 51, No. 12 ( 2020-06), p. 1406-1416
    Abstract: Virus, host factors and their interplay influence Hepatitis B surface Antigen serum levels during Hepatitis B Virus (HBV) infection course and treatment. Aim To study the Pre‐S/S circulating quasispecies in a cohort of untreated, HBeAg negative, genotype‐D, HBsAg carriers. Methods We studied 260 carriers: 71 with HBeAg negative infection (ENI; HBV‐DNA ≤2000 IU/mL); 42 Grey Zone (GZ; HBV‐DNA ≤20 000 IU/mL); 82 chronic hepatitis (CH) and 65 cirrhosis (CI) (HBV‐DNA  〉  20 000 IU/mL). Population sequencing was applied to identify Pre‐S/S gene mutations responsible for any amino acid substitution or potential biological/antigenic implications (M‐muts) on HBsAg. Results HBsAg serum levels were lower in ENI + GZ than in CH + CI (2.61 [−1.10/4.06] vs 3.62 [2.41/4.92] log 10 IU/mL, P   〈  0.001) and in CI than CH (3.48 [2.41/4.38] vs 3.66 [2.57/4.92] log 10 IU/mL, P   〈  0.001). M‐muts were found in 73 (28.1%) cases: 5 (7.0%) ENI, 3 (7.1%) GZ, 26 (31.7%) CH, 39 (60.0%) CI ( P   〈  0.001) and mostly in Pre‐S2 (17.6%) than Pre‐S1 (5.8%) and Small‐S (10.8%; P   〈  0.001). Overall HBsAg serum levels were higher in carriers with M‐muts (3.56 [0.95/4.38] vs 3.17 [−1.10/4.92] log 10 IU/mL, P   〈  0.001), but comparable in carriers with or without M‐mut when considering separately ENI + GZ (2.84 [0.95/3.89] vs 2.61 [−1.10/4.06] log 10 IU/mL, P  = 0.330] and CH + CI (3.57 [2.67/4.38] vs 3.63 [2.41/4.92] log 10 IU/mL, P  = 0.37). Infection phase ( β : 0.422, P   〈  0.001), age ( β : −0.260, P   〈  0.001), ALT ( β : −0.103, P  = 0.045), liver stiffness ( β : −0.118, P  = 0.039) and HBV‐DNA ( β : 0.384, P   〈  0.001), but not M‐mut were independently associated with HBsAg serum levels. Conclusions In HBeAg negative, genotype‐D, carriers Pre‐S/S heterogeneity increases with severity of liver disease, but does not influence HBsAg serum levels, that in low viraemic carriers are associated with an effective control of HBV.
    Type of Medium: Online Resource
    ISSN: 0269-2813 , 1365-2036
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2003094-0
    SSG: 15,3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages